ClinicalTrials.gg
CompletedNCT02809573Updated Jul 24, 2019

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

A Phase 1 interventional study of Chidamide and cyclophosphamide in Peripheral T-cell Lymphoma, sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral — 17 open to participants now, 18 under way, 2 of them phase 3. tucidinostat · Lymphoma, T-Cell, Peripheral.

Enrollment
23rd of 29
30 · median 44
Started
2016
with 3 others
Phase 1
2 of 29
none open now
Registered
2nd of 29
by date
Lead sponsor
2 of 29
Chipscreen Biosciences, Ltd.

Among the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, this one is the 23rd largest by enrollment, is one of 4 that started in 2016, is one of 2 in phase 1, and was the 2nd registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

17 of the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral are open now, in 2 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chidamide in a range of doses combined with CHOP in fixed dose in patients with newly diagnosed peripheral T-cell lymphoma.

Read the detailed description

The purpose of this study is to assess the tolerability and safety include adverse events, vital signs, laboratory tests, etc., of a range of doses of chidamide combined with CHOP in peripheral T-cell lymphoma patients, and to determine the dose limit toxicity and the maximum tolerable dose.

03

Conditions studied

  • Peripheral T-cell Lymphoma

Keywords

  • peripheral T-cell lymphoma
  • PTCL
  • chidamide
  • CHOP
  • phase Ib
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female aged 18-65 years old;
  2. Histopathologically confirmed Peripheral T -cell Lymphoma (PTCL) including:

    • PTCL-unspecified;
    • Angioimmunoblastic T-cell lymphoma;
    • Anaplastic large cell lymphoma, ALK positive or negative;
    • Subcutaneous panniculitis T-cell lymphoma;
    • Cutaneous / T-cell lymphoma;
    • Other T-cell lymphoma that investigators consider to be appropriate to be enrolled;
  3. Patients have not received anti-tumor therapy;
  4. In any Ann Arbor disease stage;
  5. performance status 0-1;
  6. Patients without bone marrow involvement. The absolute number of neutrophile is no less then 2.0 * 10\^9/L, no less then 100 * 10\^9/L. And the concentration of is no less than 110 g/L;
  7. is no less than 6 months;
  8. Patients who have signed the Form.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have central nervous system or meninges involvements;
  2. Patients have been treated by radiotherapy, chemotherapy or immunotherapy for PTCL;
  3. Patients have uncontrollable or significant cardiovascular disease including:

    • history of myocardial infarction;
    • uncontrollable angina within the 6 months before screening, or taking anti-angina drugs at the time of screening;
    • history of congestive heart failure, or the (LVEF) is \< 50% at the time of screening;
    • ventricular arrhythmia such as ventricular tachycardia, ventricular fibrillation or torsades de pointes;
    • History of supraventricular arrhythmia or nodal arrhythmia that could not been controlled by drug or need a pacemaker;
    • History of cardiomyopathy;
    • History of clinically significant prolongation, or QTc interval > 450 ms at screening;
    • Coronary disease which is with symptoms and needs drug therapy;
  4. Patients have undergone organ transplantation;
  5. Patients with thromboembolic disease, hematencephalon or cerebral infraction within 4 weeks before screening, or patients who are under anticoagulant therapy;
  6. Patients with clinically significant abnormalities in gastrointestinal tract, such as dysphagia, chronic diarrhea and intestinal obstruction which may affect the uptake,transformation and absorption of the drug;
  7. Patients with active infections, including active bacterial,viral,fungoid, mycobacterium, parasite infections (but not including hyponychium fungoid infection), or infections which need not be treated by intravenous antibody therapies, or antiviral therapies, or any serious infection need to be treated by hospitalization;
  8. Patients who have been conducted the surgery on a major organ in less than 6 weeks;
  9. Hepatic function: Serum total > 1.5 fold of normal range; /AST > 2.5 folds of normal range or 5 folds for liver ; Renal function: Serum creatine > 1.5 folds of normal range;
  10. Patients with other in the past or now (except basal cell carcinoma, squamous-cell carcinoma or carcinoma in situs of cervix that has been adequately treated),unless the malignancy has been radically treated and there has been no evidence of recurrence for 5 years;
  11. Pregnant or lactating women and patients in childbearing age who will not carry out ;
  12. Patients with mental disorders, which may affect understanding and execution of or the compliance of the study;
  13. Drug abuse or long term alcoholism that could affect the evaluation for the study results;
  14. Patients considered by investigators not suitable for the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    study drugs

    Lead-in period is 4 days. Patients take a single dose of Chidamide tablet, then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle. Cyclophosphamide, adriacin and vincristine are given in intravenous infusion on Day 1. On Day 1 to 5, prednisone is given orally. Treatment cycles are repeated every 3 weeks .The combination therapy lasts for at most 6 cycles. Patients enter the single agent therapy if attained complete response after 6-cycle combination therapy. In this stage, patients take chidamide orally on Day 1, 4, 8 and 11 of each cycle.

    Drug: Chidamide · Drug: cyclophosphamide · Drug: adriacin · Drug: vincristine · Drug: prednisone

Interventions

  • In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.

    Also known as: CS055

  • On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m\^2 in 5 minutes after chidamide administration

    Also known as: CTX

  • On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m\^2 soon after cyclophosphamide administration.

    Also known as: ADR

  • On Day 1, vincristine is given in IV infusion at 1.4 mg/m\^2 after adriacin administration.

    Also known as: VCR

  • On Day 1 to 5, prednisone is given orally at 100 mg once a day

    Also known as: PED

06

What researchers measure

Primary outcomes

  1. dose-limiting toxicity (DLT)

    Time frame: Day 1 - 21

Secondary outcomes

  1. Adverse events

    Time frame: About 21 weeks

  2. complete response rate

    Time frame: About 21 weeks

  3. Duration of response

    Time frame: About 21 weeks

  4. Progression free survival

    Time frame: About 21 weeks

  5. Objective response rate

    Time frame: About 21 weeks

  6. Overall survival

    Time frame: About 21 weeks

  7. Area under the concentration versus time curve (AUC)

    Time frame: Day 1 of the lead-in period and Day 1 of the combination therapy

  8. Peak plasma concentration (Cmax)

    Time frame: Day 1 of the lead-in period and Day 1 of the combination therapy

  9. Time of Cmax (Tmax)

    Time frame: Day 1 of the lead-in period and Day 1 of the combination therapy

07

Study locations

1 site
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jan 2019, 28 months.

Of 42 phase 1 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 61. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2016
First posted
Jun 22, 2016
StartActual
Aug 11, 2016
Primary completionActual
Jan 8, 2019
CompletionActual
Jan 8, 2019
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02809573
Responsible party
Sponsor
First posted
Jun 22, 2016
Start date
Aug 11, 2016
Primary completion
Jan 8, 2019
Completion
Jan 8, 2019
Last update
Jul 24, 2019

Study contacts

Yuankai Shi, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucidinostat

Start the discussion